Phathom Pharmaceuticals, Inc.PHATEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Jennison Associates LLC | 10.40% | 7.0M | — | 2024-11-04 |
| Frazier Life Sciences IX, L.P. | 8.50% | 5.8M | ▼ -1.50pp | 2024-08-22 |
| Medicxi Growth I LP | 6.40% | 3.7M | — | 2024-01-26 |
| The Carlyle Group Inc. | 6.10% | 3.5M | — | 2024-02-12 |
| OF ABOVE PERSONS | 5.50% | 3.2M | — | 2024-02-09 |
| BlackRock, Inc. | 5.20% | 3.1M | flat | 2024-11-12 |
| Takeda Pharmaceutical Company Limited | 4.80% | 2.8M | ▼ -0.60pp | 2024-04-10 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-10 | Asit Parikh | Director | Gift | 40.0K | $0.00 | $0 |
| 2026-03-10 | Asit Parikh | Director | Gift | 40.0K | $0.00 | $0 |
| 2026-02-27 | Breedlove Robert Charles | Principal Accounting Officer | Grant | 13.0K | $0.00 | $0 |
| 2026-02-27 | Breedlove Robert Charles | Principal Accounting Officer | Grant | 2.8K | $0.00 | $0 |
| 2026-02-10 | Basta Steven L | President and CEO | Grant | 12.4K | $0.00 | $0 |
| 2026-02-10 | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | Grant | 3.5K | $0.00 | $0 |
1–6 of 6